➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Boehringer Ingelheim
Baxter
Johnson and Johnson
Harvard Business School

Last Updated: July 24, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,096,569


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,096,569
Title:Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Inventor(s): deLong; Mitchell A. (Chapel Hill, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Davis, CA)
Assignee: Aerie Pharmaceuticals, Inc. (Research Triangle Park, NC)
Application Number:14/273,895
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,096,569

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aerie Pharms Inc RHOPRESSA netarsudil mesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE ⤷  Free Forever Trial
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,096,569

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009273932 ⤷  Free Forever Trial
Canada 2731869 ⤷  Free Forever Trial
European Patent Office 2326623 ⤷  Free Forever Trial
Spain 2474150 ⤷  Free Forever Trial
Japan 2011529074 ⤷  Free Forever Trial
Japan 2014208681 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.